Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2025 Filed Feb 7, 2025 21:56 UTC |
Herr Amy E.Director
|
GrantStock Option (Right to Buy) · Derivative | 2,415 | $0.00 Strike: $72.05 | $0.00 |
DisclosureSEC source: 0001062993-25-001897 · form4.xml · derivative · entry 3 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,415 Underlying: Common Stock · 2,415 shares Expires 2035-02-03 F1 · derivative.exercise_date: The option vests on the earlier of the one-year anniversary of the grant date or the date of Bio-Techne's annual meeting of shareholders. Read SEC document |
| February 03, 2025 Filed Feb 7, 2025 21:56 UTC |
Herr Amy E.Director
|
GrantCommon Stock | 1,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-001897 · form4.xml · nonDerivative · entry 2 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,040 Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 22:31 UTC |
McManus MatthewPresident - DGS
|
Exercise / conversionRestricted Stock Units · Derivative | 4,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-001660 · form4.xml · derivative · entry 5 McManus Matthew · CIK 0001908268 · President - DGS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,241 Underlying: Common Stock · 4,620 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: 4,620 restricted stock units vest on 2/1/2025 and 2/1/2027, and 4,621 restricted stock units vest on 2/1/2026. F3 · derivative.expiration_date: 4,620 restricted stock units vest on 2/1/2025 and 2/1/2027, and 4,621 restricted stock units vest on 2/1/2026. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 22:31 UTC |
McManus MatthewPresident - DGS
|
Tax withholdingCommon Stock | 1,642 | $73.55 | $120,769.10 |
DisclosureSEC source: 0001062993-25-001660 · form4.xml · nonDerivative · entry 2 McManus Matthew · CIK 0001908268 · President - DGS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,978 Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 22:31 UTC |
McManus MatthewPresident - DGS
|
Exercise / conversionCommon Stock | 4,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-001660 · form4.xml · nonDerivative · entry 1 McManus Matthew · CIK 0001908268 · President - DGS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 22:27 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
Exercise / conversionRestricted Stock Units · Derivative | 3,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-001659 · form4.xml · derivative · entry 3 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: 3,320 restricted stock units vest on 2/1/2025. F2 · derivative.expiration_date: 3,320 restricted stock units vest on 2/1/2025. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 22:27 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
Tax withholdingCommon Stock | 1,109 | $73.55 | $81,566.95 |
DisclosureSEC source: 0001062993-25-001659 · form4.xml · nonDerivative · entry 2 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,292 Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 22:27 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
Exercise / conversionCommon Stock | 3,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-001659 · form4.xml · nonDerivative · entry 1 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:35 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 13,392 | $0.00 Strike: $37.70 | $0.00 |
DisclosureSEC source: 0001062993-25-001237 · form4.xml · derivative · entry 4 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,392 shares Expires 2025-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:35 UTC |
Kelderman KimDirector · Chief Executive Officer
|
SaleCommon Stock | 1,661 | $77.95 | $129,479.93 |
DisclosureSEC source: 0001062993-25-001237 · form4.xml · nonDerivative · entry 3 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,004 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.69 to $78.08 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:35 UTC |
Kelderman KimDirector · Chief Executive Officer
|
SaleCommon Stock | 11,731 | $77.19 | $905,533.49 |
DisclosureSEC source: 0001062993-25-001237 · form4.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,665 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.67 to $77.66 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:35 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 13,392 | $37.70 | $504,878.40 |
DisclosureSEC source: 0001062993-25-001237 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:48 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
Exercise / conversionRestricted Stock Units · Derivative | 9,912 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-018335 · form4.xml · derivative · entry 11 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,911 Underlying: Common Stock · 9,912 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F8 · derivative.exercise_date: 9,911 restricted stock units vest on 11/1/2025. F8 · derivative.expiration_date: 9,911 restricted stock units vest on 11/1/2025. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:48 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
Tax withholdingCommon Stock | 3,270 | $75.31 | $246,263.70 |
DisclosureSEC source: 0001062993-24-018335 · form4.xml · nonDerivative · entry 2 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,081 Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:48 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
Exercise / conversionCommon Stock | 9,912 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-018335 · form4.xml · nonDerivative · entry 1 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:47 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 2,430 | $75.31 | $183,003.30 |
DisclosureSEC source: 0001062993-24-018334 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,004 Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:46 UTC |
Hippel JamesCFO
|
GrantRestricted Stock Units · Derivative | 34,634 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-018333 · form4.xml · derivative · entry 18 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,634 Underlying: Common Stock · 34,634 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F12 · derivative.exercise_date: 11,545 restricted stock units vest on each of 11/1/2025 and 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027. F12 · derivative.expiration_date: 11,545 restricted stock units vest on each of 11/1/2025 and 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:46 UTC |
Hippel JamesCFO
|
Exercise / conversionRestricted Stock Units · Derivative | 13,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-018333 · form4.xml · derivative · entry 14 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,159 Underlying: Common Stock · 13,159 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F8 · derivative.exercise_date: On 11/1/2024, the Board of Directors certified vesting of ____ performance RSUs. The remaining 13,159 restricted stock units vest on 11/1/2025. F8 · derivative.expiration_date: On 11/1/2024, the Board of Directors certified vesting of ____ performance RSUs. The remaining 13,159 restricted stock units vest on 11/1/2025. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:46 UTC |
Hippel JamesCFO
|
Tax withholdingCommon Stock | 6,475 | $75.31 | $487,632.25 |
DisclosureSEC source: 0001062993-24-018333 · form4.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,610 Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:46 UTC |
Hippel JamesCFO
|
Exercise / conversionCommon Stock | 13,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-018333 · form4.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:44 UTC |
KEEGAN JOSEPH DDirector
|
GrantStock Options (Right to Buy) · Derivative | 3,511 | $0.00 Strike: $68.37 | $0.00 |
DisclosureSEC source: 0001062993-24-018034 · form4.xml · derivative · entry 9 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,511 Underlying: Common Stock · 3,511 shares Expires 2034-10-24 F1 · derivative.exercise_date: This option vests on the earlier of the one year anniversary of the grant date (10/24/2024) or the date of Bio-Techne's 2025 annual meeting of shareholders. Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:44 UTC |
KEEGAN JOSEPH DDirector
|
GrantCommon Stock | 1,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-018034 · form4.xml · nonDerivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,771 Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:43 UTC |
Vessey RupertDirector
|
GrantStock Options (Right to Buy) · Derivative | 3,511 | $0.00 Strike: $68.37 | $0.00 |
DisclosureSEC source: 0001062993-24-018033 · form4.xml · derivative · entry 8 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,511 Underlying: Common Stock · 3,511 shares Expires 2034-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2024) or the date of Bio-Techne's 2025 annual meeting of shareholders. Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:43 UTC |
Vessey RupertDirector
|
GrantCommon Stock | 1,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-018033 · form4.xml · nonDerivative · entry 1 VESSEY RUPERT · CIK 0001677618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,347 Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:42 UTC |
Bushman Julie LDirector
|
GrantStock Options (Right to Buy) · Derivative | 3,511 | $0.00 Strike: $68.37 | $0.00 |
DisclosureSEC source: 0001062993-24-018032 · form4.xml · derivative · entry 7 Bushman Julie L · CIK 0001518599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,511 Underlying: Common Stock · 3,511 shares Expires 2034-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2024) or the date of Bio-Techne's 2025 annual meeting of shareholders. Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:42 UTC |
Bushman Julie LDirector
|
GrantCommon Stock | 1,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-018032 · form4.xml · nonDerivative · entry 1 Bushman Julie L · CIK 0001518599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,135 Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:42 UTC |
HIGGINS JOHN LDirector
|
GrantStock Options (Right to Buy) · Derivative | 3,511 | $0.00 Strike: $68.37 | $0.00 |
DisclosureSEC source: 0001062993-24-018031 · form4.xml · derivative · entry 11 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,511 Underlying: Common Stock · 3,511 shares Expires 2034-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2024) or the date of Bio-Techne's 2025 annual meeting of shareholders. Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:42 UTC |
HIGGINS JOHN LDirector
|
GrantCommon Stock | 1,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-018031 · form4.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,196 Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:41 UTC |
Nusse RoelandDirector
|
GrantStock Options (Right to Buy) · Derivative | 3,511 | $0.00 Strike: $68.37 | $0.00 |
DisclosureSEC source: 0001062993-24-018030 · form4.xml · derivative · entry 11 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,511 Underlying: Common Stock · 3,511 shares Expires 2034-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2024) or the date of Bio-Techne's 2025 annual meeting of shareholders. Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:41 UTC |
Nusse RoelandDirector
|
GrantCommon Stock | 1,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-018030 · form4.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,559 Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:41 UTC |
Seth AlpnaDirector
|
GrantStock Options (Right to Buy) · Derivative | 3,511 | $0.00 Strike: $68.37 | $0.00 |
DisclosureSEC source: 0001062993-24-018029 · form4.xml · derivative · entry 7 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,511 Underlying: Common Stock · 3,511 shares Expires 2034-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2024) or the date of Bio-Techne's 2025 annual meeting of shareholders. Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:41 UTC |
Seth AlpnaDirector
|
GrantCommon Stock | 1,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-018029 · form4.xml · nonDerivative · entry 1 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,771 Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:40 UTC |
Klimovsky Judith V.Director
|
GrantStock Option (Right to Buy) · Derivative | 3,511 | $0.00 Strike: $68.37 | $0.00 |
DisclosureSEC source: 0001062993-24-018028 · form4.xml · derivative · entry 3 Klimovsky Judith V · CIK 0001762247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,511 Underlying: Common Stock · 3,511 shares Expires 2034-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2024) or the date of Bio-Techne's 2025 annual meeting of shareholders. Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:40 UTC |
Klimovsky Judith V.Director
|
GrantCommon Stock | 1,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-018028 · form4.xml · nonDerivative · entry 1 Klimovsky Judith V · CIK 0001762247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,142 Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:40 UTC |
BAUMGARTNER ROBERT VDirector
|
GrantStock Options (Right to Buy) · Derivative | 3,511 | $0.00 Strike: $68.37 | $0.00 |
DisclosureSEC source: 0001062993-24-018027 · form4.xml · derivative · entry 11 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,511 Underlying: Common Stock · 3,511 shares Expires 2034-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2024) or the date of Bio-Techne's 2025 annual meeting of shareholders. Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 20:40 UTC |
BAUMGARTNER ROBERT VDirector
|
GrantCommon Stock | 1,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-018027 · form4.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,863 Read SEC document |
| September 12, 2024 Filed Sep 16, 2024 20:18 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $22.95 | $0.00 |
DisclosureSEC source: 0001062993-24-016642 · form4.xml · derivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2024-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 12, 2024 Filed Sep 16, 2024 20:18 UTC |
HIGGINS JOHN LDirector
|
Tax withholdingCommon Stock | 1,874 | $73.20 | $137,176.80 |
DisclosureSEC source: 0001062993-24-016642 · form4.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,734 Read SEC document |
| September 12, 2024 Filed Sep 16, 2024 20:18 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionCommon Stock | 6,000 | $22.95 | $137,700.00 |
DisclosureSEC source: 0001062993-24-016642 · form4.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 20:05 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,492 | $0.00 Strike: $66.97 | $0.00 |
DisclosureSEC source: 0001062993-24-015997 · form4.xml · derivative · entry 5 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,724 Underlying: Common Stock · 1,492 shares Expires 2027-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 20:05 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 1,492 | $66.97 | $99,919.24 |
DisclosureSEC source: 0001062993-24-015997 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:30 UTC |
Hippel JamesCFO
|
GrantStock Options (Right to Buy) · Derivative | 32,417 | $0.00 Strike: $74.91 | $0.00 |
DisclosureSEC source: 0001062993-24-015387 · form4.xml · derivative · entry 16 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,417 Underlying: Common Stock · 32,417 shares Expires 2034-08-15 F11 · derivative.exercise_date: Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:30 UTC |
Hippel JamesCFO
|
GrantRestricted Stock Units · Derivative | 12,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015387 · form4.xml · derivative · entry 15 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,031 Underlying: Common Stock · 12,031 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F10 · derivative.exercise_date: 4,010 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 4,011 restricted stock units vest on 8/15/2027. F10 · derivative.expiration_date: 4,010 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 4,011 restricted stock units vest on 8/15/2027. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:30 UTC |
Hippel JamesCFO
|
GrantPerformance Restricted Stock Units · Derivative | 24,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015387 · form4.xml · derivative · entry 14 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,062 Underlying: Common Stock · 24,062 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F9 · derivative.exercise_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F9 · derivative.expiration_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:29 UTC |
Kelderman KimDirector · Chief Executive Officer
|
GrantStock Options (Right to Buy) · Derivative | 69,061 | $0.00 Strike: $74.91 | $0.00 |
DisclosureSEC source: 0001062993-24-015385 · form4.xml · derivative · entry 19 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,061 Underlying: Common Stock · 69,061 shares Expires 2034-08-15 F12 · derivative.exercise_date: Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:29 UTC |
Kelderman KimDirector · Chief Executive Officer
|
GrantRestricted Stock Units · Derivative | 25,630 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015385 · form4.xml · derivative · entry 18 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,630 Underlying: Common Stock · 25,630 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: 8,543 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027. F11 · derivative.expiration_date: 8,543 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:29 UTC |
Kelderman KimDirector · Chief Executive Officer
|
GrantPerformance Restricted Stock Units · Derivative | 51,261 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015385 · form4.xml · derivative · entry 17 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,261 Underlying: Common Stock · 51,261 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F10 · derivative.expiration_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:29 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
GrantStock Options (Right to Buy) · Derivative | 21,204 | $0.00 Strike: $74.91 | $0.00 |
DisclosureSEC source: 0001062993-24-015384 · form4.xml · derivative · entry 13 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,204 Underlying: Common Stock · 21,204 shares Expires 2034-08-15 F12 · derivative.exercise_date: Options to purchase 5,301 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:29 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
GrantRestricted Stock Units · Derivative | 7,869 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015384 · form4.xml · derivative · entry 12 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,869 Underlying: Common Stock · 7,869 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: 2,623 restricted stock units vest on each of 8/15/2025, 8/15/2026 and 8/15/2027. F11 · derivative.expiration_date: 2,623 restricted stock units vest on each of 8/15/2025, 8/15/2026 and 8/15/2027. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:29 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
GrantPerformance Restricted Stock Units · Derivative | 15,738 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015384 · form4.xml · derivative · entry 11 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,738 Underlying: Common Stock · 15,738 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F10 · derivative.expiration_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.